NASDAQ: RAPP
Rapport Therapeutics Inc Stock Ownership - Who owns Rapport Therapeutics?

Insider buying vs selling

Have Rapport Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Cheryl GaultChief Operating Officer2026-03-052,014$28.93
$58.27kSell
David BredtChief Scientific Officer2026-02-196,000$1.80
$10.80kBuy
Abraham CeesayChief Executive Officer2026-02-183,552$29.05
$103.19kSell
Abraham CeesayChief Executive Officer2026-02-182,983$29.04
$86.64kSell
Abraham CeesayChief Executive Officer2026-02-182,100$29.80
$62.57kSell
Abraham CeesayChief Executive Officer2026-02-182,281$29.80
$67.97kSell
David BredtChief Scientific Officer2026-02-172,200$29.59
$65.11kSell
David BredtChief Scientific Officer2026-02-17900$28.02
$25.22kSell
David BredtChief Scientific Officer2026-02-175,400$28.95
$156.33kSell
Abraham CeesayChief Executive Officer2026-01-205,083$26.11
$132.74kSell

1 of 6

RAPP insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RAPP insiders and whales buy or sell their stock.

RAPP Shareholders

What type of owners hold Rapport Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Third Rock Ventures V LP16.96%8,104,451$240.13MInsider
Trv GP V LLC14.93%7,135,233$211.42MInstitution
Fmr LLC14.88%7,111,865$210.72MInstitution
Arch Venture Partners XII LLC7.80%3,728,738$110.48MInsider
Arch Venture Management LLC7.80%3,728,738$110.48MInstitution
Capital International Investors7.12%3,402,529$100.82MInstitution
Cormorant Asset Management LP6.33%3,027,521$89.71MInstitution
Goldman Sachs Group Inc6.28%3,001,879$88.95MInstitution
Blackrock Inc5.09%2,431,862$72.06MInstitution
James Healy4.18%1,995,594$59.13MInsider

1 of 3

RAPP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RAPP76.03%23.97%Net SellingNet Selling
ARDX42.21%57.79%Net BuyingNet Buying
ATAI15.31%25.40%Net Buying
NKTR41.27%58.73%Net SellingNet Selling
TRVI43.05%56.95%Net Buying

Rapport Therapeutics Stock Ownership FAQ

Who owns Rapport Therapeutics?

Rapport Therapeutics (NASDAQ: RAPP) is owned by 106.89% institutional shareholders, 33.70% Rapport Therapeutics insiders, and 0.00% retail investors. Third Rock Ventures V LP is the largest individual Rapport Therapeutics shareholder, owning 8.10M shares representing 16.96% of the company. Third Rock Ventures V LP's Rapport Therapeutics shares are currently valued at $247.51M.

If you're new to stock investing, here's how to buy Rapport Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.